Oncotarget

Research Papers:

High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients

Yu-Jen Cheng, Yi-Chen Lee, Wen-Chin Chiu, Jen-Wei Tsai, Yu-Han Su, Amos C. Hung, Po-Chih Chang, Chih-Jen Huang, Chee-Yin Chai and Shyng-Shiou F. Yuan _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:11564-11575. https://doi.org/10.18632/oncotarget.2595

Metrics: PDF 1236 views  |   HTML 1548 views  |   ?  


Abstract

Yu-Jen Cheng1,2, Yi-Chen Lee3, Wen-Chin Chiu4, Jen-Wei Tsai5, Yu-Han Su6, Amos C. Hung6, Po-Chih Chang7, Chih-Jen Huang8, Chee-Yin Chai9 and Shyng-Shiou F. Yuan6,10

1 Division of Thoracic Surgery, Department of Surgery, and Cancer Center, E-DA Hospital, Kaohsiung, Taiwan

2 Department of Postgraduate Medicine, School of Medicine for International Student, I-Shou University, Kaohsiung, Taiwan

3 Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

4 Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

5 Department of Anatomic Pathology, E-DA Hospital, Kaohsiung, Taiwan

6 Translational Research Center, Department of Medical Research, and Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

7 Division of General Surgery, Department of Surgery, E-DA Hospital, Kaohsiung, Taiwan

8 Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

9 Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

10 School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence:

Shyng-Shiou F. Yuan, email:

Keywords: Id1, non-small-cell lung cancer, oncogene addiction, disease-free survival, overall survival, adjuvant chemotherapy

Received: August 03, 2014 Accepted: October 18, 2014 Published: October 18, 2014

Abstract

Adjuvant chemotherapy is commonly given to surgically treated non-small-cell lung cancer (NSCLC) patients. However, the prerequisite for chemotherapy needs to be scrutinized in order to maximize the benefits to patients. In this study, we observed that NSCLC cells with high Id1 protein expression were vulnerable to the treatment of paclitaxel and cisplatin. In addition, paclitaxel and cisplatin caused Id1 protein degradation through ubiquitination. In the nude mice xenograft model, the tumor growth was reduced to a large degree in the Id1-overexpressing group upon treatment with paclitaxel and cisplatin. Furthermore, immunohistochemical staining for Id1 followed by Kaplan-Meier survival analysis showed that surgically treated NSCLC patients with high Id1 expression in primary tumor tissues had better disease-free and overall survivals after adjuvant paclitaxel and cisplatin chemotherapy. In summary, our current data suggest that Id1, a generally negative prognostic factor, predicts a favorable prognosis in the case of surgically treated NSCLC patients receiving the definitive adjuvant chemotherapy. The distinct role of Id1 reported in this study may arise from the phenomenon of Id1 dependence of NSCLC cells for survival, which renders the cancer cells additionally susceptive to the adjuvant chemotherapy with paclitaxel and cisplatin.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2595